v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at beginning at Dec. 31, 2024 $ 368,634 $ 94 $ 1,291,095 $ 160 $ (922,715)
Balance at beginning (in shares) at Dec. 31, 2024   93,823,678      
Unrealized loss on marketable securities (31)     (31)  
Exercise of stock options 5,038   5,038    
Exercise of stock options (in shares)   375,939      
Issuance of common shares upon RSU vesting   $ 1 (1)    
Issuance of common shares upon RSU vesting (in shares)   673,790      
Equity-based compensation expense 13,413   13,413    
Other 2   2    
Net loss (74,723)       (74,723)
Balance at end at Mar. 31, 2025 312,333 $ 95 1,309,547 129 (997,438)
Balance at end (in shares) at Mar. 31, 2025   94,873,407      
Balance at beginning at Dec. 31, 2024 368,634 $ 94 1,291,095 160 (922,715)
Balance at beginning (in shares) at Dec. 31, 2024   93,823,678      
Unrealized loss on marketable securities (102)        
Foreign currency translation adjustments 0        
Net loss (184,754)        
Balance at end at Jun. 30, 2025 233,293 $ 96 1,340,608 58 (1,107,469)
Balance at end (in shares) at Jun. 30, 2025   95,999,608      
Balance at beginning at Mar. 31, 2025 312,333 $ 95 1,309,547 129 (997,438)
Balance at beginning (in shares) at Mar. 31, 2025   94,873,407      
Unrealized loss on marketable securities (71)     (71)  
Exercise of stock options 3,262   3,262    
Exercise of stock options (in shares)   275,874      
Issuance of common shares upon RSU vesting (in shares)   392,283      
Exercise of common warrants 3,367 $ 1 3,366    
Exercise of common warrants (in shares)   458,044      
Equity-based compensation expense 24,433   24,433    
Foreign currency translation adjustments 0        
Net loss (110,031)       (110,031)
Balance at end at Jun. 30, 2025 233,293 $ 96 1,340,608 58 (1,107,469)
Balance at end (in shares) at Jun. 30, 2025   95,999,608      
Balance at beginning at Dec. 31, 2025 245,488 $ 108 1,545,940 94 (1,300,654)
Balance at beginning (in shares) at Dec. 31, 2025   108,461,354      
Unrealized loss on marketable securities (71)     (71)  
Sale of common shares, net of issuance costs 111,774 $ 3 111,771    
Sale of common shares, net of issuance costs (in shares)   2,576,299      
Exercise of stock options 5,420   5,420    
Exercise of stock options (in shares)   415,289      
Issuance of common shares upon vesting of restricted stock units ("RSUs") and performance stock units ("PSUs")   $ 1 (1)    
Issuance of common shares upon vesting of restricted stock units ("RSUs") and performance stock units ("PSUs") (in shares)   846,766      
Exercise of common warrants   $ 7 (7)    
Exercise of common warrants (in shares)   6,804,066      
Equity-based compensation expense 18,245   18,245    
Foreign currency translation adjustments 667     667  
Net loss (105,510)       (105,510)
Balance at end at Mar. 31, 2026 276,013 $ 119 1,681,368 690 (1,406,164)
Balance at end (in shares) at Mar. 31, 2026   119,103,774      
Balance at beginning at Dec. 31, 2025 245,488 $ 108 1,545,940 94 (1,300,654)
Balance at beginning (in shares) at Dec. 31, 2025   108,461,354      
Unrealized loss on marketable securities (109)        
Foreign currency translation adjustments 1,156        
Net loss (215,406)        
Balance at end at Jun. 30, 2026 253,784 $ 122 1,768,581 1,141 (1,516,060)
Balance at end (in shares) at Jun. 30, 2026   121,600,396      
Balance at beginning at Mar. 31, 2026 276,013 $ 119 1,681,368 690 (1,406,164)
Balance at beginning (in shares) at Mar. 31, 2026   119,103,774      
Unrealized loss on marketable securities (38)     (38)  
Sale of common shares, net of issuance costs 49,000 $ 1 48,999    
Sale of common shares, net of issuance costs (in shares)   967,393      
Exercise of stock options 11,406 $ 1 11,405    
Exercise of stock options (in shares)   932,079      
Issuance of common shares upon RSU vesting   $ 1 (1)    
Issuance of common shares upon RSU vesting (in shares)   347,150      
Exercise of common warrants 7,148   7,148    
Exercise of common warrants (in shares)   250,000      
Equity-based compensation expense 19,662   19,662    
Foreign currency translation adjustments 489     489  
Net loss (109,896)       (109,896)
Balance at end at Jun. 30, 2026 $ 253,784 $ 122 $ 1,768,581 $ 1,141 $ (1,516,060)
Balance at end (in shares) at Jun. 30, 2026   121,600,396